Why the study?
Does cardiac resynchronization therapy improve outcomes in heart failure patients with LVEF >35%?
Does cardiac resynchronization therapy improve outcomes in heart failure patients with LVEF >35%?
This review highlights emerging evidence that cardiac resynchronization therapy may benefit heart failure patients with LVEF >35%, suggesting a potential expansion of current indications.
Answers are grounded in this paper and cite their sources.
Should not yet expand CRT indications beyond LVEF ≤35%; leaves open need for prospective RCTs to confirm benefit.
Cardiac resynchronization therapy is beneficial in heart failure patients with LVEF ≤35% and electrical dyssynchrony. However, its effects among patients with less severe LV dysfunction have not been established. Recent post-hoc analyses of landmark CRT trials suggest that CRT benefit may be present in patients with LVEF >35% and is associated with improvement in cardiac reverse remodelling, all-cause mortality, and need for heart failure hospitalizations. This review summarizes the currently available literature regarding the potential impact of CRT in patients with more modest reductions in LVEF.
No takes yet. Share an insight, caveat, or question.
Hai et al. (2014) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: